MNMD logo

MNMD
Mind Medicine Inc - Ordinary Shares (Sub Voting)

25,986
Mkt Cap
$1.05B
Volume
2.13M
52W High
$14.43
52W Low
$4.70
PE Ratio
-5.96
MNMD Fundamentals
Price
$11.75
Prev Close
$10.68
Open
$10.69
50D MA
$11.75
Beta
1.71
Avg. Volume
2.16M
EPS (Annual)
-$1.54
P/B
6.91
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
FY2025 Earnings Estimate for MNMD Issued By Chardan Capital
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD - Free Report) - Analysts at Chardan Capital issued their FY2025 earnings estimates for Mind Medicine (MindMed) in a research note issued to investors on...
MarketBeat·23h ago
News Placeholder
More News
News Placeholder
Persistent Asset Partners Ltd Invests $238,000 in Mind Medicine (MindMed) Inc. $MNMD
Persistent Asset Partners Ltd acquired a new stake in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD - Free Report) during the second quarter, according to its most recent Form 13F filing with the SEC...
MarketBeat·8d ago
News Placeholder
HC Wainwright Issues Pessimistic Forecast for MNMD Earnings
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD - Free Report) - Investment analysts at HC Wainwright dropped their FY2025 earnings per share (EPS) estimates for shares of Mind Medicine (MindMed) in a...
MarketBeat·11d ago
News Placeholder
Leerink Partnrs Has Pessimistic View of MNMD Q4 Earnings
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD - Free Report) - Investment analysts at Leerink Partnrs reduced their Q4 2025 earnings estimates for Mind Medicine (MindMed) in a research report issued to...
MarketBeat·12d ago
News Placeholder
Canaccord Genuity Group Forecasts Strong Price Appreciation for Mind Medicine (MindMed) (NASDAQ:MNMD) Stock
Canaccord Genuity Group lifted their price objective on Mind Medicine (MindMed) from $16.00 to $25.00 and gave the company a "buy" rating in a report on Friday...
MarketBeat·16d ago
News Placeholder
Royal Bank Of Canada Lowers Mind Medicine (MindMed) (NASDAQ:MNMD) Price Target to $20.00
Royal Bank Of Canada reduced their target price on Mind Medicine (MindMed) from $21.00 to $20.00 and set an "outperform" rating on the stock in a report on Friday...
MarketBeat·16d ago
News Placeholder
MindMed Reports Q3 2025 Financial Results and Business Updates
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the 'Company' or 'MindMed'), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today...
Business Wire·18d ago
News Placeholder
MindMed to Participate in Upcoming Investor Conferences
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the Company or MindMed), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today...
Business Wire·20d ago
News Placeholder
MindMed Announces New Employee Inducement Grant
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the Company or MindMed), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today...
Business Wire·21d ago
News Placeholder
MindMed to Report Q3 2025 Financial Results on November 6, 2025
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the Company or MindMed), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today...
Business Wire·25d ago

Latest MNMD News

View

Advertisement|Remove ads.

Advertisement|Remove ads.